BOSTON, MA, UNITED STATES – June 17, 2025 – LarmorBio™, a Massachusetts Institute of Technology (MIT) spinout pioneering the use of microscale magnetic resonance (MMR) for life sciences research and clinical diagnostics, announced today that its proprietary oxidative stress platform, Marlin_MR™, will be introduced at the upcoming Endocrine Society 2025 Annual Meeting (ENDO 2025), taking place in San Francisco from July 12–15, 2025.

In addition to showcasing the platform, LarmorBio will present new clinical data on three abstracts at the meeting including:

A new study utilizing LarmorBio’s proprietary microscale magnetic resonance (MMR) platform presented at the European Atherosclerosis Society (EAS) meeting has demonstrated the ability of the system to identify early warning signs of vascular dysfunction in patients at risk for cardiometabolic disease. The study showed that LarmorBio’s oxidative stress measurement in plasma was highly correlated with established risk metrics for cardiovascular risk and vascular function. It is well known that oxidative stress plays a critical role in vascular damage and cardiometabolic disease progression. However, while prior preclinical studies have shown the correlation of the company’s test with organ damage, this is the first study demonstrating the link between LarmorBio’s oxidative stress test and vascular damage in humans.

Technology

BOSTON MA, UNITED STATES, March 17, 2025 – LarmorBio, a Massachusetts Institute of Technology (MIT) start-up pioneering the use of microscale magnetic resonance (MR) for life sciences research and clinical diagnostics, is announcing the recent expansion of its board of directors and senior executive team with seasoned life science executives. The company makes these changes as it anticipates scaling the business commercially in the second half of 2025.

LarmorBio, a Massachusetts Institute of Technology (MIT) start-up pioneering the use of microscale magnetic resonance (MMR) relaxometry for life sciences research and clinical diagnostics, is announcing several recent peer-reviewed publications. These publications build upon the supporting evidence that MMR can be used to non-invasively assess cellular senescence, viability, and proliferation without the need for dye or antibody labelling, enabling early, near real-time intervention that is impossible with today’s bioprocessing methods. These milestones represent a significant step toward addressing critical unmet needs in scalable cell and gene manufacturing. MMR holds the promise to improve cell potency, reduce contamination risk and improve production yields in an entirely new way.

A new editorial article in the Lancet Journal highlights the emerging clinical need to detect and treat prediabetic patients and the significant need for a rapid, low cost blood test to better identify these patients.

Currently in the United States nearly half of heart attacks and strokes occur in patients that are not deemed high-risk by traditional risk factors such as high blood pressure, high cholesterol, and diabetes…

Inflammatory bowel disease (IBD) is a chronic immune-mediated condition that affects the digestive system and includes Crohn’s disease (CD) and ulcerative colitis (UC)…

Reactive Oxygen Species (ROS) are produced as a byproduct of cellular metabolism and can damage DNA, proteins, and lipids, promoting genomic instability and oncogenic signalling pathways…

Oxidative stress has been suggested to play a key role in multiple sclerosis (MS), but clinical data on oxidative stress markers in MS patients were inconsistent…